Mga Batayang Estadistika
| LEI | 724500BUT8GAG9LMYN56 |
| CIK | 1809122 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to CureVac N.V.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 15, 2025 |
Exhibit 99.1 CureVac N.V. Unaudited Interim Condensed Consolidated Financial Statements As of June 30, 2025 and December 31, 2024 and for the three and six months ended June 30, 2025 and 2024 CureVac N.V. Unaudited Interim Condensed Consolidated Statements of Operations and Other Comprehensive Income (Loss) Three months ended June 30, Six months ended June 30, (in thousands of EUR, except per shar |
|
| August 15, 2025 |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The following discussion and analysis of our financial condition and results of operations provides information that we believe to be relevant to an assessment and understanding of our results of operations and financial condition for the periods described. This discussion should be read in conjuncti |
|
| August 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2025 Commission File Number: 001-39446 CureVac N.V. (Exact Name of Registrant as Specified in Its Charter) Friedrich-Miescher-Strasse 15, 72076 Tübingen, Germany +49 7071 9883 0 (Address of |
|
| August 11, 2025 |
425 Filed by BioNTech SE (Commission File No. 001-39081) pursuant to Rule 425 under the Securities Act of 1933, as amended and deemed filed pursuant to Rule 14d-2(b) under the Securities Exchange Act of 1934, as amended. Subject Company: CureVac N.V. Commission File No.: 001-39446 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURS |
|
| August 8, 2025 |
Filed by BioNTech SE (Commission File 425 Filed by BioNTech SE (Commission File No. 001-39081) pursuant to Rule 425 under the Securities Act of 1933, as amended and deemed filed pursuant to Rule 14d-2(b) under the Securities Exchange Act of 1934, as amended. Subject Company: CureVac N.V. Commission File No.: 001-39446 The following communications are being filed in connection with the proposed acquisition of CureVac N.V. by BioNTech S |
|
| August 8, 2025 |
CureVac Announces Resolution of Patent Litigation with Pfizer/BioNTech Exhibit 99.1 CureVac Announces Resolution of Patent Litigation with Pfizer/BioNTech TÜBINGEN, Germany / BOSTON, USA – August 7/8, 2025 – CureVac N.V. (Nasdaq: CVAC), a pioneering multinational biotech company developing a new class of transformative medicines based on messenger RNA (mRNA), today announced that CureVac N.V. and an affiliate (together, “CureVac”), and an affiliate of GSK plc (LSE/NY |
|
| August 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2025 Commission File Number: 001-39446 CureVac N.V. (Exact Name of Registrant as Specified in Its Charter) Friedrich-Miescher-Strasse 15, 72076 Tübingen, Germany +49 7071 9883 0 (Address |
|
| June 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2025 Commission File Number: 001-39446 CureVac N.V. (Exact Name of Registrant as Specified in Its Charter) Friedrich-Miescher-Strasse 15, 72076 Tübingen, Germany +49 7071 9883 0 (Address o |
|
| June 26, 2025 |
Exhibit 99.1 CureVac N.V., Tübingen, Germany Annual General Meeting of Shareholders, June 24, 2025 Voting results – Overview Agenda Item 3 Adoption of the annual accounts over the financial year 2024 - accepted 140.238.267 Number of shares for which valid votes were cast (= 62.28 % of the registered share capital) 140.132.699 Yes votes 99.97 % of the valid votes cast 29.971 No votes 0.02 % of the |
|
| June 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2025 Commission File Number: 001-39446 CureVac N.V. (Exact Name of Registrant as Specified in Its Charter) Friedrich-Miescher-Strasse 15, 72076 Tübingen, Germany +49 7071 9883 0 (Address o |
|
| June 24, 2025 |
CureVac Announces Voting Results of General Meeting Exhibit 99.1 CureVac Announces Voting Results of General Meeting TÜBINGEN, Germany / BOSTON, USA – June 24, 2025 – CureVac N.V. (Nasdaq: CVAC), a pioneering multinational biotech company developing a new class of transformative medicines based on messenger RNA (mRNA), today announced the voting results of the Company's Annual General Meeting. The shareholders of the Company voted in favor of all p |
|
| June 17, 2025 |
425 Filed by BioNTech SE (Commission File No. 001-39081) pursuant to Rule 425 under the Securities Act of 1933, as amended and deemed filed pursuant to Rule 14d-2(b) under the Securities Exchange Act of 1934, as amended. Subject Company: CureVac N.V. Commission File No.: 001-39446 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURS |
|
| June 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2025 Commission File Number: 001-39446 CureVac N.V. (Exact Name of Registrant as Specified in Its Charter) Friedrich-Miescher-Strasse 15, 72076 Tübingen, Germany +49 7071 9883 0 (Address o |
|
| June 16, 2025 |
Exhibit 99.1 Execution Version PURCHASE AGREEMENT dated as of June 12, 2025 by and between BIONTECH SE and CUREVAC N.V. TABLE OF CONTENTS Page Article 1 DEFINITIONS Section 1.01 Definitions 2 Section 1.02 Other Definitional and Interpretative Provisions 22 Article 2 THE OFFER Section 2.01 The Offer 22 Section 2.02 Company Action 27 Section 2.03 Equity Awards 28 Section 2.04 Extraordinary General M |
|
| June 12, 2025 |
Filed by BioNTech SE (Commission File No. 001-39081) pursuant to Rule 425 under the Securities Act of 1933, as amended and deemed filed pursuant to Rule 14d-2(b) under the Securities Exchange Act of 1934, as amended. Subject Company: CureVac N.V. Commission File No.: 001-39446 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT |
|
| June 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 CureVac N.V. (Name of Subject Company) CureVac N.V. (Name of Persons Filing Statement) Common shares, par value €0.12 per share (Title of Class of Securities) N2451R105 (CUSIP Number of Class of Sec |
|
| June 12, 2025 |
Exhibit 99.4 This page is hosted on CureVac’s internal intranet, accessible only to CureVac employees. This page is available in both English and German. A New Chapter Begins — Joining Forces with BioNTech Dear RNA people, Today marks a truly exciting and historic moment for CureVac – and for each one of us who has passionately advanced the science of mRNA. We are excited to announce that CureVac |
|
| June 12, 2025 |
BioNTech Acquisition of CureVac Questions & Answers 425 Filed by BioNTech SE (Commission File No. 001-39081) pursuant to Rule 425 under the Securities Act of 1933, as amended and deemed filed pursuant to Rule 14d-2(b) under the Securities Exchange Act of 1934, as amended. Subject Company: CureVac N.V. Commission File No.: 001-39446 The following communications are being filed in connection with the proposed acquisition of CureVac N.V. by BioNTech S |
|
| June 12, 2025 |
Social Media Post on LinkedIn CureVac N.V. Exhibit 99.9 Social Media Post on LinkedIn CureVac N.V. Alexander Zehnder, CEO of CureVac N.V., posted to its LinkedIn account the following: Today marks a truly exciting and historic moment for CureVac – and for each one of us who has passionately advanced the science of mRNA. I’m excited to announce that we entered into a definitive Purchase Agreement with BioNTech, another pioneering German lea |
|
| June 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2025 Commission File Number: 001-39446 CureVac N.V. (Exact Name of Registrant as Specified in Its Charter) Friedrich-Miescher-Strasse 15, 72076 Tübingen, Germany +49 7071 9883 0 (Address o |
|
| June 12, 2025 |
Filed by BioNTech SE (Commission File 425 Filed by BioNTech SE (Commission File No. 001-39081) pursuant to Rule 425 under the Securities Act of 1933, as amended and deemed filed pursuant to Rule 14d-2(b) under the Securities Exchange Act of 1934, as amended. Subject Company: CureVac N.V. Commission File No.: 001-39446 The following communications are being filed in connection with the proposed acquisition of CureVac N.V. by BioNTech S |
|
| June 12, 2025 |
This document is strictly confidential and for internal use only – do not forward. |
|
| June 12, 2025 |
Exhibit 99.5 This email was supplied to CureVac employees to share with external partners. Both English and German versions of this email were provided. Dear [Insert Contact Name], We recently announced that CureVac has entered into a definitive Purchase Agreement with BioNTech, pursuant to which BioNTech intends to acquire all of the shares of CureVac. This transaction will bring together two pio |
|
| June 12, 2025 |
Exhibit 99.6 This email was supplied to CureVac employees to share with investigators. Both English and German versions of this email were provided. Dear [Insert Investigator Contact Name], We recently announced that CureVac has entered into a definitive Purchase Agreement with BioNTech, pursuant to which BioNTech intends to acquire all of the shares of CureVac. This transaction will bring togethe |
|
| June 12, 2025 |
Communication principles and guidelines for social media activity 12.06.2025 1 Do’s Don’ts ✓ Speak with one voice - Post the link to the announcement press release or our Corporate social media post to your own social media accounts ✓ Limit personal social media posts to pre-approved messaging only, which can be found on the following slide. Always include the following sentence in your posts: For |
|
| June 12, 2025 |
BioNTech Announces Strategic Transaction to Acquire CureVac in Public Exchange Offer Exhibit 99.1 BioNTech Announces Strategic Transaction to Acquire CureVac in Public Exchange Offer · Acquisition will strengthen the research, development, manufacturing and commercialization of mRNA-based cancer immunotherapy candidates, marking BioNTech’s next key milestone in the execution of its oncology strategy · Acquisition of CureVac will complement BioNTech’s capabilities and proprietary t |
|
| June 12, 2025 |
BioNTech Announces Strategic Transaction to Acquire CureVac in Public Exchange Offer Exhibit 99.1 BioNTech Announces Strategic Transaction to Acquire CureVac in Public Exchange Offer · Acquisition will strengthen the research, development, manufacturing and commercialization of mRNA-based cancer immunotherapy candidates, marking BioNTech’s next key milestone in the execution of its oncology strategy · Acquisition of CureVac will complement BioNTech’s capabilities and proprietary t |
|
| June 12, 2025 |
Filed by BioNTech SE (Commission File 425 Filed by BioNTech SE (Commission File No. 001-39081) pursuant to Rule 425 under the Securities Act of 1933, as amended and deemed filed pursuant to Rule 14d-2(b) under the Securities Exchange Act of 1934, as amended. Subject Company: CureVac N.V. Commission File No.: 001-39446 The following communications are being filed in connection with the proposed acquisition of CureVac N.V. by BioNTech S |
|
| June 12, 2025 |
Social Media Post on LinkedIn CureVac N.V. Exhibit 99.8 Social Media Post on LinkedIn CureVac N.V. CureVac posted to its LinkedIn account the following: Today marks a new chapter for CureVac as we entered into a definitive Purchase Agreement with BioNTech, another pioneering German leader in mRNA innovation, pursuant to which BioNTech intends to acquire all of the shares of CureVac. This transaction brings together two deeply complementary |
|
| June 12, 2025 |
Filed by BioNTech SE (Commission File 425 Filed by BioNTech SE (Commission File No. 001-39081) pursuant to Rule 425 under the Securities Act of 1933, as amended and deemed filed pursuant to Rule 14d-2(b) under the Securities Exchange Act of 1934, as amended. Subject Company: CureVac N.V. Commission File No.: 001-39446 The following communications are being filed in connection with the proposed acquisition of CureVac N.V. by BioNTech S |
|
| June 12, 2025 |
A New Chapter Begins – Joining Forces with BioNTech Exhibit 99.2 This email was sent by the members of CureVac N.V.’s management board to all CureVac employees after the press release was published. A New Chapter Begins – Joining Forces with BioNTech Dear RNA people, Today marks a truly exciting and historic moment for CureVac – and for each one of us who has passionately advanced the science of mRNA. We are excited to announce that CureVac has ent |
|
| May 23, 2025 |
Exhibit 99.1 CONVENING NOTICE This is the convening notice for the annual general meeting of CureVac N.V. (the "Company") to be held at the offices of NautaDutilh N.V. (address: Beethovenstraat 400, 1082 PR Amsterdam, the Netherlands) on 24 June 2025 at 2:00 p.m. Central European Summer Time (the "AGM"). The agenda for the AGM is as follows: 1. Opening 2. Discussion of the annual report over the f |
|
| May 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2025 Commission File Number: 001-39446 CureVac N.V. (Exact Name of Registrant as Specified in Its Charter) Friedrich-Miescher-Strasse 15, 72076 Tübingen, Germany +49 7071 9883 0 (Address of p |
|
| May 23, 2025 |
Exhibit 99.2 Signature [PLEASE SIGN WITHIN BOX] Date Signature (Joint Owners) Date TO VOTE, MARK BLOCKS BELOW IN BLUE OR BLACK INK AS FOLLOWS: KEEP THIS PORTION FOR YOUR RECORDS DETACH AND RETURN THIS PORTION ONLY THIS PROXY CARD IS VALID ONLY WHEN SIGNED AND DATED. V75521-P30526 For Against Abstain ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! VOTE BY INTERNET - ww |
|
| May 20, 2025 |
CureVac Announces Financial Results for the First Quarter of 2025 and Provides Business Updates Exhibit 99.1 CureVac Announces Financial Results for the First Quarter of 2025 and Provides Business Updates · U.S. FDA clears lung cancer IND for CVHNLC, a proprietary off-the-shelf candidate targeting squamous non-small cell lung cancer (sqNCLC), with clinical study expected to begin H2 2025; Clinical Trial Application filed in Europe with decision expected in Q2 2025 · Glioblastoma study fully |
|
| May 20, 2025 |
Exhibit 99.1 CureVac N.V. Unaudited Interim Condensed Consolidated Financial Statements As of March 31, 2025 and December 31, 2024 and for the three months ended March 31, 2025 and 2024 CureVac N.V. Unaudited Interim Condensed Consolidated Statements of Operations and Other Comprehensive Income (Loss) Three months ended March 31, (in thousands of EUR, except per share amounts) Note 2024 2025 Reven |
|
| May 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2025 Commission File Number: 001-39446 CureVac N.V. (Exact Name of Registrant as Specified in Its Charter) Friedrich-Miescher-Strasse 15, 72076 Tübingen, Germany +49 7071 9883 0 (Address of pr |
|
| May 20, 2025 |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The following discussion and analysis of our financial condition and results of operations provides information that we believe to be relevant to an assessment and understanding of our results of operations and financial condition for the periods described. This discussion should be read in conjuncti |
|
| May 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2025 Commission File Number: 001-39446 CureVac N.V. (Exact Name of Registrant as Specified in Its Charter) Friedrich-Miescher-Strasse 15, 72076 Tübingen, Germany +49 7071 9883 0 (Address of pr |
|
| May 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2025 Commission File Number: 001-39446 CureVac N.V. (Exact Name of Registrant as Specified in Its Charter) Friedrich-Miescher-Strasse 15, 72076 Tübingen, Germany +49 7071 9883 0 (Address of pr |
|
| May 15, 2025 |
Exhibit 99.1 CureVac Receives Additional Positive Validity Decision from European Patent Office in Ongoing Litigation Against BioNTech SE · European Patent Office largely dismisses opposition filed by BioNTech SE, Pfizer Inc., and others in December 2023 challenging validity of EP 4 023 755 B1 and maintains the patent subject to amendments to specific patent claims · A hearing on infringement of E |
|
| April 11, 2025 |
Consent of Independent Registered Public Accounting Firm Exhibit 15.2 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the Registration Statement (Form S-8 No. 333-246197) as amended, pertaining to the CureVac N.V. Long-Term Incentive Plan, CureVac Virtual Share Plan, and Employment Agreement between CureVac AG and a Former Employee; of our report dated April 25, 2023, with respect to the consolida |
|
| April 11, 2025 |
Exhibit 12.1 CERTIFICATION BY THE CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Alexander Zehnder, certify that: 1. I have reviewed this annual report on Form 20-F of CureVac N.V.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of t |
|
| April 11, 2025 |
Exhibit 13.2 CERTIFICATION BY THE CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 The certification set forth below is being submitted in connection with the Annual Report on Form 20-F of CureVac N.V. (the “Report”) for the purpose of complying with Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 19 |
|
| April 11, 2025 |
Exhibit 13.1 CERTIFICATION BY THE CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 The certification set forth below is being submitted in connection with the Annual Report on Form 20-F of CureVac N.V. (the “Report”) for the purpose of complying with Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 19 |
|
| April 11, 2025 |
INSIDER TRADING POLICY CUREVAC N.V. Exhibit 11.1 INSIDER TRADING POLICY CUREVAC N.V. INTRODUCTION Article 1 This document sets out the Company’s insider trading policy. DEFINITIONS AND INTERPRETATION Article 2 2.1In this policy the following definitions shall apply: Ad Hoc Black-Out Period A period designated by the CEO or CFO or the GC as described in Article 4.2. Article An article of this policy. Black-Out Period Each period that |
|
| April 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF |
|
| April 11, 2025 |
Consent of Independent Registered Public Accounting Firm Exhibit 15.1 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the registration statement (No. 333-246197) on Form S-8 of our reports dated April 10, 2025, with respect to the consolidated financial statements of CureVac N.V. and the effectiveness of internal control over financial reporting. /s/ KPMG AG Wirtschaftsprüfungsgesellschaft Stuttga |
|
| April 11, 2025 |
LICENCE AGREEMENT June 2024 by and between CUREVAC SE GLAXOSMITHKLINE BIOLOGICALS SA Exhibit 4.36 LICENCE AGREEMENT dated June 2024 by and between CUREVAC SE and GLAXOSMITHKLINE BIOLOGICALS SA TABLE OF CONTENTS 1. Definitions 5 2. Licences; Exclusivity 23 3. Development, Manufacturing and Commercialisation. 31 4. Consideration and Payments. 33 5. Intellectual Property 43 6. Enforcement and Defence. 44 7. Confidentiality 48 8. Compliance; Quality 52 9. Indemnification; Representati |
|
| April 11, 2025 |
Exhibit 12.2 CERTIFICATION BY THE CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Axel Malkomes, certify that: 1. I have reviewed this annual report on Form 20-F of CureVac N.V.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the c |
|
| April 10, 2025 |
Exhibit 99.1 CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2024 and Provides Business Update Strategic Milestone Achievement and Increased Financial Discipline Underscore Year of Corporate Transformation · Completed enrollment of Part B of Phase 1 glioblastoma study with investigational precision immunotherapy CVGBM; Part B first data readout anticipated in H2 2025 · Fil |
|
| April 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2025 Commission File Number: 001-39446 CureVac N.V. (Exact Name of Registrant as Specified in Its Charter) Friedrich-Miescher-Strasse 15, 72076 Tübingen, Germany +49 7071 9883 0 (Address of |
|
| April 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2025 Commission File Number: 001-39446 CureVac N.V. (Exact Name of Registrant as Specified in Its Charter) Friedrich-Miescher-Strasse 15, 72076 Tübingen, Germany +49 7071 9883 0 (Address of |
|
| April 7, 2025 |
Exhibit 99.1 CureVac Receives U.S. FDA IND Clearance to Initiate Phase 1 Clinical Trial for Novel mRNA-Based Precision Immunotherapy in Squamous Non-Small Cell Lung Cancer · Significant Regulatory Milestone: U.S. FDA cleared IND application for CVHNLC, CureVac’s investigational therapy targeting squamous non-small cell lung cancer · Proprietary Epitopes: CVHNLC encodes novel tumor epitopes identif |
|
| March 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2025 Commission File Number: 001-39446 CureVac N.V. (Exact Name of Registrant as Specified in Its Charter) Friedrich-Miescher-Strasse 15, 72076 Tübingen, Germany +49 7071 9883 0 (Address of |
|
| March 27, 2025 |
Exhibit 99.1 CureVac Receives Positive Validity Decision from European Patent Office in Litigation Against BioNTech SE · European Patent Office largely dismisses opposition filed by BioNTech SE in April 2023 challenging validity of EP 3 708 668 B1 and maintains the patent in amended form · A hearing on infringement of EP 3 708 668 B1 is scheduled for July 1, 2025, before the Regional Court Düsseld |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2024 Commission File Number: 001-39446 CureVac N.V. (Exact Name of Registrant as Specified in Its Charter) Friedrich-Miescher-Strasse 15, 72076 Tübingen, Germany +49 7071 9883 0 (Address |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2024 Commission File Number: 001-39446 CureVac N.V. (Exact Name of Registrant as Specified in Its Charter) Friedrich-Miescher-Strasse 15, 72076 Tübingen, Germany +49 7071 9883 0 (Address |
|
| November 12, 2024 |
Exhibit 99.1 CureVac N.V. Unaudited Interim Condensed Consolidated Financial Statements As of September 30, 2024 and December 31, 2023 and for the three and nine months ended September 30, 2024 and 2023 CureVac N.V. Interim Condensed Consolidated Statements of Operations and Other Comprehensive Income (Loss) Three months ended September 30, Nine months ended September 30, Note 2023 2024 2023 2024 |
|
| November 12, 2024 |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The following discussion and analysis of our financial condition and results of operations provides information that we believe to be relevant to an assessment and understanding of our results of operations and financial condition for the periods described. This discussion should be read in conjuncti |
|
| November 12, 2024 |
Exhibit 99.1 CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2024 and Provides Business Update Strengthened Cash, Strategic Refocus and Pipeline Progress Define Transformative Quarter • €400 million upfront payment from restructured GSK collaboration reflected in financials, cash position increased to €551 million; expected cash runway re-affirmed into 2028 • CVG |
|
| November 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2024 Commission File Number: 001-39446 CureVac N.V. (Exact Name of Registrant as Specified in Its Charter) Friedrich-Miescher-Strasse 15, 72076 Tübingen, Germany +49 7071 9883 0 (Address |
|
| November 4, 2024 |
CureVac to Present at the 12th International mRNA Health Conference Exhibit 99.1 CureVac to Present at the 12th International mRNA Health Conference TÜBINGEN, Germany/BOSTON, USA – November 4, 2024 – CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced that new and updated data will be shared in two oral presentations and four pos |
|
| November 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2024 Commission File Number: 001-39446 CureVac N.V. (Exact Name of Registrant as Specified in Its Charter) Friedrich-Miescher-Strasse 15, 72076 Tübingen, Germany +49 7071 9883 0 (Address |
|
| November 4, 2024 |
Exhibit 99.1 CureVac Strengthens Leadership Team with Appointment of Seasoned Industry Executive Axel Sven Malkomes as Chief Financial Officer • Experienced CFO and investment banker with 30-year track record will help drive CureVac’s transformation TÜBINGEN, Germany/BOSTON, USA – November 4, 2024 – CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class |
|
| September 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2024 Commission File Number: 001-39446 CureVac N.V. (Exact Name of Registrant as Specified in Its Charter) Friedrich-Miescher-Strasse 15, 72076 Tübingen, Germany +49 7071 9883 0 (Address |
|
| September 13, 2024 |
Exhibit 99.1 CureVac’s CVGBM Cancer Vaccine Induces Promising Immune Responses in Phase 1 Study in Glioblastoma Presented at the ESMO 2024 Congress · Preliminary immunogenicity results demonstrate induction of cancer antigen-specific T-cell responses in 77% of evaluable patients following CVGBM monotherapy · 84% of immune responses were de novo, observed in patients without pre-existing T-cell act |
|
| September 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2024 Commission File Number: 001-39446 CureVac N.V. (Exact Name of Registrant as Specified in Its Charter) Friedrich-Miescher-Strasse 15, 72076 Tübingen, Germany +49 7071 9883 0 (Address |
|
| September 12, 2024 |
CureVac Partner GSK Announces Positive Phase 2 Data from Seasonal Influenza mRNA Vaccine Program Exhibit 99.1 CureVac Partner GSK Announces Positive Phase 2 Data from Seasonal Influenza mRNA Vaccine Program · Phase 2 data demonstrated positive immune responses to A and B strains, with acceptable safety and reactogenicity profile, meeting all pre-defined study endpoints · Vaccine candidate based on CureVac’s proprietary second-generation mRNA backbone · GSK confirmed data support advancing pro |
|
| September 9, 2024 |
CureVac to Present First CVGBM Glioblastoma Cancer Vaccine Clinical Data at ESMO 2024 Congress Exhibit 99.1 CureVac to Present First CVGBM Glioblastoma Cancer Vaccine Clinical Data at ESMO 2024 Congress TÜBINGEN, Germany/BOSTON, USA – September 9, 2024 – CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced that the first clinical data from CureVac’s ongoing |
|
| September 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2024 Commission File Number: 001-39446 CureVac N.V. (Exact Name of Registrant as Specified in Its Charter) Friedrich-Miescher-Strasse 15, 72076 Tübingen, Germany +49 7071 9883 0 (Address |
|
| August 15, 2024 |
Exhibit 99.1 CureVac N.V. Unaudited Interim Condensed Consolidated Financial Statements As of June 30, 2024 and December 31, 2023 and for the three and six months ended June 30, 2024 and 2023 CureVac N.V. Interim Condensed Consolidated Statements of Operations and Other Comprehensive Income (Loss) Three months ended June 30, Six months ended June 30, Note 2023 2024 2023 2024 (in thousands of EUR, |
|
| August 15, 2024 |
Exhibit 99.1 CureVac Announces Financial Results for the Second Quarter and First Half of 2024 and Provides Business Update · Closed new licensing agreement with GSK worth up to €1.45 billion, including €400 million upfront; provides strong validation of CureVac’s mRNA platform · Initiated strategic workforce reduction of ~30% by end of 2024, optimizing business to focus on high-value opportunitie |
|
| August 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2024 Commission File Number: 001-39446 CureVac N.V. (Exact Name of Registrant as Specified in Its Charter) Friedrich-Miescher-Strasse 15, 72076 Tübingen, Germany +49 7071 9883 0 (Address o |
|
| August 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2024 Commission File Number: 001-39446 CureVac N.V. (Exact Name of Registrant as Specified in Its Charter) Friedrich-Miescher-Strasse 15, 72076 Tübingen, Germany +49 7071 9883 0 (Address of |
|
| August 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2024 Commission File Number: 001-39446 CureVac N.V. (Exact Name of Registrant as Specified in Its Charter) Friedrich-Miescher-Strasse 15, 72076 Tübingen, Germany +49 7071 9883 0 (Address of |
|
| August 15, 2024 |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The following discussion and analysis of our financial condition and results of operations provides information that we believe to be relevant to an assessment and understanding of our results of operations and financial condition for the periods described. This discussion should be read in conjuncti |
|
| August 15, 2024 |
CureVac Names Oncologist and Drug Development Expert Dr. Mehdi Shahidi to Supervisory Board Exhibit 99.1 CureVac Names Oncologist and Drug Development Expert Dr. Mehdi Shahidi to Supervisory Board TÜBINGEN, Germany/BOSTON, USA – August 15, 2024 – CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today named clinical oncologist Mehdi Shahidi, M.D., as an independent d |
|
| August 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2024 Commission File Number: 001-39446 CureVac N.V. (Exact Name of Registrant as Specified in Its Charter) Friedrich-Miescher-Strasse 15, 72076 Tübingen, Germany +49 7071 9883 0 (Address of |
|
| August 15, 2024 |
Exhibit 99.1 CureVac Advances Cancer Vaccine Candidate CVGBM to Part B of Phase 1 Study in Patients with Resected Glioblastoma · First patient administered in dose-confirmation Part B of Phase 1 study with mRNA-based, multiepitope cancer vaccine candidate CVGBM · Part B expected to include up to 20 patients to generate extended data on safety, tolerability, and immunogenicity of CVGBM TÜBINGEN, Ge |
|
| July 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2024 Commission File Number: 001-39446 CureVac N.V. (Exact Name of Registrant as Specified in Its Charter) Friedrich-Miescher-Strasse 15, 72076 Tübingen, Germany +49 7071 9883 0 (Address of p |
|
| July 11, 2024 |
Exhibit 99.1 CureVac Provides Update on Trial Dates for Patent Litigation Across Multiple Geographies Against Pfizer/BioNTech · New trial date for U.S. patent litigation set for March 3, 2025, following settlement with Acuitas Therapeutics · First instance decision on validity of EP 3 708 668 B1 (split poly-A tail technology) scheduled for March 25, 2025, by European Patent Office in the context o |
|
| July 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2024 Commission File Number: 001-39446 CureVac N.V. (Exact Name of Registrant as Specified in Its Charter) Friedrich-Miescher-Strasse 15, 72076 Tübingen, Germany +49 7071 9883 0 (Address of p |
|
| July 3, 2024 |
GSK and CureVac to Restructure Collaboration into New Licensing Agreement Exhibit 99.1 GSK and CureVac to Restructure Collaboration into New Licensing Agreement · GSK acquires full rights to develop, manufacture and commercialize globally mRNA candidate vaccines for influenza and COVID-19, including combinations · CureVac receives €400 million upfront and up to an additional €1.05 billion in development, regulatory and sales milestone payments as well as tiered royaltie |
|
| July 3, 2024 |
Exhibit 99.2 CureVac Initiates Strategic Restructuring to Align Resources with Focus on High-Value mRNA Pipeline Opportunities · Strategic restructuring includes a workforce reduction of approximately 30%, re-focusing on research, development, and innovation to create leaner and more agile organization · Prioritization of high-value opportunities in oncology and other selected diseases, leveraging |
|
| June 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2024 Commission File Number: 001-39446 CureVac N.V. (Exact Name of Registrant as Specified in Its Charter) Friedrich-Miescher-Strasse 15, 72076 Tübingen, Germany +49 7071 9883 0 (Address of p |
|
| June 26, 2024 |
Exhibit 99.1 CureVac N.V., Tübingen, Germany General Meeting of Shareholders, June 24, 2024 Voting results – Overview Agenda Item 3 Adoption of the annual accounts over the financial year 2023 - accepted 144.861.897 Number of shares for which valid votes were cast (= 64.58 % of the registered share capital) 144.753.185 Yes votes 99.98 % of the valid votes cast 20.809 No votes 0.01 % of the valid v |
|
| June 24, 2024 |
CureVac Announces Voting Results of General Meeting Exhibit 99.1 CureVac Announces Voting Results of General Meeting TÜBINGEN, Germany/BOSTON, USA – June 24, 2024 – CureVac N.V. (Nasdaq: CVAC), a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced the voting results of the Company's annual general meeting. The shareholders of the Company vot |
|
| June 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2024 Commission File Number: 001-39446 CureVac N.V. (Exact Name of Registrant as Specified in Its Charter) Friedrich-Miescher-Strasse 15, 72076 Tübingen, Germany +49 7071 9883 0 (Address of p |
|
| May 28, 2024 |
Exhibit 99.1 CureVac Announces Dosing of First Participant in a Phase 2 Study in Seasonal Influenza; Development in Collaboration with GSK · Phase 2 study to assess updated formulations for improved immune responses of multivalent vaccine candidate against influenza B strain · Study initiated following previously reported interim data from Phase 2 Part of combined Phase 1/2 study in seasonal influ |
|
| May 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 Commission File Number: 001-39446 CureVac N.V. (Exact Name of Registrant as Specified in Its Charter) Friedrich-Miescher-Strasse 15, 72076 Tübingen, Germany +49 7071 9883 0 (Address of pr |
|
| May 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2024 Commission File Number: 001-39446 CureVac N.V. (Exact Name of Registrant as Specified in Its Charter) Friedrich-Miescher-Strasse 15, 72076 Tübingen, Germany +49 7071 9883 0 (Address of p |
|
| May 24, 2024 |
Exhibit 99.2 CUREVAC N.V. FRIEDRICH-MIESCHER-STRASSE 15 TUEBINGEN 72076 GERMANY SCAN TO VIEW MATERIALS & VOTE VOTE BY INTERNET - www.proxyvote.com or scan the QR Barcode above Use the Internet to transmit your voting instructions and for electronic delivery of information. Vote by 23:59 p.m. CEST on 21 June 2024. Have your proxy card in hand when you access the web site and follow the instructions |
|
| May 24, 2024 |
Exhibit 99.1 CONVENING NOTICE This is the convening notice for the annual general meeting of CureVac N.V. (the "Company") to be held at the offices of NautaDutilh N.V. (address: Beethovenstraat 400, 1082 PR Amsterdam, the Netherlands) on June 24, 2024 at 2:00 p.m. Central European Summer Time (the "AGM"). The agenda for the AGM is as follows: 1. Opening 2. Discussion of the annual report over the |
|
| May 23, 2024 |
Exhibit 99.1 CureVac N.V. Unaudited Interim Condensed Consolidated Financial Statements As of March 31, 2024 and December 31, 2023 and for the three months ended March 31, 2024 and 2023 CureVac N.V. Interim Condensed Consolidated Statements of Operations and Other Comprehensive Income (Loss) Three months ended March 31, Note 2023 2024 (in thousands of EUR, except per share amounts) (unaudited) Rev |
|
| May 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 Commission File Number: 001-39446 CureVac N.V. (Exact Name of Registrant as Specified in Its Charter) Friedrich-Miescher-Strasse 15, 72076 Tübingen, Germany +49 7071 9883 0 (Address of pr |
|
| May 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2024 Commission File Number: 001-39446 CureVac N.V. (Exact Name of Registrant as Specified in Its Charter) Friedrich-Miescher-Strasse 15, 72076 Tübingen, Germany +49 7071 9883 0 (Address of p |
|
| May 23, 2024 |
CureVac Announces Financial Results for the First Quarter of 2024 and Provides Business Update Exhibit 99.1 CureVac Announces Financial Results for the First Quarter of 2024 and Provides Business Update · Organizational redesign on track, trimming residual pandemic infrastructure and reducing 150 positions by year end · U.S. FDA Fast Track designation granted for pre-pandemic avian influenza (H5N1) vaccine currently in Phase 1 development; candidate jointly developed with GSK · Settlement w |
|
| May 23, 2024 |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The following discussion and analysis of our financial condition and results of operations provides information that we believe to be relevant to an assessment and understanding of our results of operations and financial condition for the periods described. This discussion should be read in conjuncti |
|
| April 25, 2024 |
REDACTED Amendment Four to Development and Option Agreement Exhibit 4.53 REDACTED Certain identified information, indicated by [*****], has been excluded from the exhibit because it is both (i) not material and (ii) the type that the registrant treats as private or confidential. Amendment Four to Development and Option Agreement This Amendment Four to the Development and Option Agreement (this "Amendment"), dated as of February 13, 2024 (the "Amendment Fou |
|
| April 25, 2024 |
REDACTED SIXTH AMENDMENT TO SPONSORED RESEARCH AGREEMENT MEE Agreement No. 2019A009504 Exhibit 4.54 REDACTED Certain identified information, indicated by [*****], has been excluded from the exhibit because it is both (i) not material and (ii) the type that the registrant treats as private or confidential. SIXTH AMENDMENT TO SPONSORED RESEARCH AGREEMENT MEE Agreement No. 2019A009504 This sixth amendment to Agreement (the “Sixth Amendment”), is effective as of June 29, 2023 (“Sixth Am |
|
| April 25, 2024 |
REDACTED 1ST AMENDMENT OF THE RESEARCH AND OPTION AGREEMENT Exhibit 4.51 REDACTED Certain identified information, indicated by [*****], has been excluded from the exhibit because it is both (i) not material and (ii) the type that the registrant treats as private or confidential. 1ST AMENDMENT OF THE RESEARCH AND OPTION AGREEMENT This 1st Amendment (“Amendment”) to the Research and Option Agreement (“Agreement”) is made and entered into effective as of 12 J |
|
| April 25, 2024 |
CUREVAC N.V. COMPENSATION RECOUPMENT POLICY Exhibit 97.1 CUREVAC N.V. COMPENSATION RECOUPMENT POLICY This CureVac N.V. Compensation Recoupment Policy (the “Policy”) has been adopted by supervisory board (the “Supervisory Board”) of CureVac N.V. (the “Company”). This Policy provides for the recoupment of certain executive compensation in the event of an accounting restatement resulting from material noncompliance with financial reporting req |
|
| April 25, 2024 |
Exhibit 4.52 REDACTED Certain identified information, indicated by [*****], has been excluded from the exhibit because it is both (i) not material and (ii) the type that the registrant treats as private or confidential. 2nd Amendment to the DEVELOPMENT AND LICENSE AGREEMENT (“Agreement”), effective as of November 9, 2017 between CureVac SE Friedrich-Miescher-Straße 15, 72076 Tübingen, Germany (her |
|
| April 25, 2024 |
Consent of Independent Registered Public Accounting Firm Exhibit 15.1 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the registration statements (No. 333-259613) on Form F-3 and (No. 333-246197) on Form S-8 of our reports dated April 24, 2024, with respect to the consolidated financial statements of CureVac N.V. and the effectiveness of internal control over financial reporting. /s/ KPMG AG Wirts |
|
| April 25, 2024 |
LONG-TERM INCENTIVE PLAN CUREVAC N.V. (Amended and Restated as of March 14, 2024) Exhibit 4.50 LONG-TERM INCENTIVE PLAN CUREVAC N.V. (Amended and Restated as of March 14, 2024) INTRODUCTION Article 1 1.1 This document sets out the Company’s long-term incentive plan for employees, officers and other service providers who qualify as Eligible Participants. 1.2 The main purposes of this Plan are: a. to attract, retain and motivate Participants with the qualities, skills and experie |
|
| April 25, 2024 |
Exhibit 13.2 CERTIFICATION BY THE CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 The certification set forth below is being submitted in connection with the Annual Report on Form 20-F of CureVac N.V. (the “Report”) for the purpose of complying with Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 19 |
|
| April 25, 2024 |
Consent of Independent Registered Public Accounting Firm Exhibit 15.2 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the following Registration Statements: (1) Registration Statement (Form F-3 No. 333-259613) of CureVac N.V., and (2) Registration Statement (Form S-8 No. 333-246197) as amended, pertaining to the CureVac N.V. Long-Term Incentive Plan, CureVac Virtual Share Plan, and Employment Agre |
|
| April 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF |
|
| April 25, 2024 |
CERTIFICATION BY THE CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF Exhibit 12.2 CERTIFICATION BY THE CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Pierre Kemula, certify that: 1. I have reviewed this annual report on Form 20-F of CureVac N.V.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the c |
|
| April 25, 2024 |
REDACTED SEVENTH AMENDMENT TO SPONSORED RESEARCH AGREEMENT SERI Agreement No. 2019A009504 Exhibit 4.55 REDACTED Certain identified information, indicated by [*****], has been excluded from the exhibit because it is both (i) not material and (ii) the type that the registrant treats as private or confidential. SEVENTH AMENDMENT TO SPONSORED RESEARCH AGREEMENT SERI Agreement No. 2019A009504 This seventh amendment to Agreement (the “Seventh Amendment”), is effective as of February 23, 2024 |
|
| April 25, 2024 |
Exhibit 13.1 CERTIFICATION BY THE CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 The certification set forth below is being submitted in connection with the Annual Report on Form 20-F of CureVac N.V. (the “Report”) for the purpose of complying with Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 19 |
|
| April 25, 2024 |
CERTIFICATION BY THE CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF Exhibit 12.1 CERTIFICATION BY THE CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Alexander Zehnder, certify that: 1. I have reviewed this annual report on Form 20-F of CureVac N.V.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of t |
|
| April 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2024 Commission File Number: 001-39446 CureVac N.V. (Exact Name of Registrant as Specified in Its Charter) Friedrich-Miescher-Strasse 15, 72076 Tübingen, Germany +49 7071 9883 0 (Address of |
|
| April 24, 2024 |
Exhibit 99.1 CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSK · Phase 1 part of combined Phase 1/2 study initiated as part of pandemic preparedness against highly pathogenic avian influenza (H5N1) virus, considered to be potential future pandemic threat · Study will assess monovalent vaccine candidate, encoding an influenza A H5-a |
|
| April 24, 2024 |
Exhibit 99.1 CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Business Update · Organizational redesign and rightsizing initiated across company to streamline structures, increase efficiency and reduce operating costs · Together with GSK, ended Pandemic Preparedness Agreement (PPA) with Federal Republic of Germany, after consultation with the German Federa |
|
| April 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2024 Commission File Number: 001-39446 CureVac N.V. (Exact Name of Registrant as Specified in Its Charter) Friedrich-Miescher-Strasse 15, 72076 Tübingen, Germany +49 7071 9883 0 (Address of |
|
| April 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2024 Commission File Number: 001-39446 CureVac N.V. (Exact Name of Registrant as Specified in Its Charter) Friedrich-Miescher-Strasse 15, 72076 Tübingen, Germany +49 7071 9883 0 (Address of |
|
| April 24, 2024 |
CureVac Appoints Thaminda Ramanayake as New Chief Business Officer Exhibit 99.1 CureVac Appoints Thaminda Ramanayake as New Chief Business Officer · Mr. Ramanayake brings more than fifteen years of experience in biopharma company development and deal-making · Strong track record of successful clinical collaborations, M&A, asset in-licensing and strategic financing initiatives across multiple therapeutic areas TÜBINGEN, Germany/BOSTON, USA – April 24, 2024 — CureV |
|
| April 16, 2024 |
CureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer Vaccines Exhibit 99.1 CureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer Vaccines · Agreement creates strong synergies between CureVac’s unique end-to-end mRNA capabilities and MD Anderson’s translational and clinical research expertise · Collaboration aims to develop novel, off-the-shelf, mRNA-based cancer vaccines in selected hematological and solid cancers with high unmet medi |
|
| April 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2024 Commission File Number: 001-39446 CureVac N.V. (Exact Name of Registrant as Specified in Its Charter) Friedrich-Miescher-Strasse 15, 72076 Tübingen, Germany +49 7071 9883 0 (Address of |
|
| April 4, 2024 |
Exhbiit 99.1 CureVac Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK · Seasonal flu vaccine candidate boosted antibody titers at all dose levels and for all encoded seasonal influenza strains across younger and older adults · Potentially differentiated, multivalent candidate encodes antigens matched to all four WHO-recommended |
|
| April 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2024 Commission File Number: 001-39446 CureVac N.V. (Exact Name of Registrant as Specified in Its Charter) Friedrich-Miescher-Strasse 15, 72076 Tübingen, Germany +49 7071 9883 0 (Address of |
|
| February 14, 2024 |
NL:CVAC / CureVac NV / RA CAPITAL MANAGEMENT, L.P. - SC 13G/A Passive Investment SC 13G/A 1 tm246065d7sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* CUREVAC N.V. (Name of Issuer) Common Shares, nominal value £0.12 per share (Title of Class of Securities) N2451R105 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check |
|
| February 14, 2024 |
EX-99.1 2 tm246065d7ex1.htm EXHIBIT 1 EXHIBIT 1 AGREEMENT This Joint Filing Agreement, dated as of February 14, 2024, is by and among RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (the foregoing are collectively referred to herein as the “Filers”). Each of the Filers may be required to file with the United States Securities and Exchange Commission |
|
| February 6, 2024 |
NL:CVAC / CureVac NV / GLAXOSMITHKLINE PLC - AMENDMENT TO FORM SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. 1)* Under the Securities Exchange Act of 1934 CureVac N.V. (Name of Issuer) Common Shares, €0.12 par value per share (Title of Class of Securities) N2451R105 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursu |
|
| January 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2024 Commission File Number: 001-39446 CureVac N.V. (Exact Name of Registrant as Specified in Its Charter) Friedrich-Miescher-Strasse 15, 72076 Tübingen, Germany +49 7071 9883 0 (Address o |
|
| January 17, 2024 |
CureVac CEO Alexander Zehnder Acquires Common Shares of Company Stock Exhibit 99.1 CureVac CEO Alexander Zehnder Acquires Common Shares of Company Stock TÜBINGEN, Germany/BOSTON, USA – January 17, 2024 – CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced that its Chief Executive Officer, Alexander Zehnder, recently purchased 50,00 |
|
| January 5, 2024 |
Exhibit 99.1 CureVac Announces Positive Phase 2 Interim Data from COVID-19 Vaccine Development Program in Collaboration with GSK Providing Strong Validation of Proprietary Technology Platform • Head-to-head comparison with licensed bivalent mRNA-based comparator vaccine confirms competitive immune responses at lower doses and favorable tolerability profile • Monovalent mRNA vaccine candidate, CV06 |
|
| January 5, 2024 |
Exhibit 99.2 |
|
| January 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2024 Commission File Number: 001-39446 CureVac N.V. (Exact Name of Registrant as Specified in Its Charter) Friedrich-Miescher-Strasse 15, 72076 Tübingen, Germany +49 7071 9883 0 (Address o |
|
| December 19, 2023 |
Exhibit 99.1 CureVac Announces Decision of German Federal Patent Court in Broad Patent Litigation with BioNTech SE · Validity of CureVac patent EP 1 857 122 B1 denied by German Federal Patent Court after nullity action filed by BioNTech SE · Decision does not affect ongoing litigation in Germany regarding seven other intellectual property rights, covering strong foundational as well as COVID-19-sp |
|
| December 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2023 Commission File Number: 001-39446 CureVac N.V. (Exact Name of Registrant as Specified in Its Charter) Friedrich-Miescher-Strasse 15, 72076 Tübingen, Germany +49 7071 9883 0 (Address |
|
| November 14, 2023 |
Exhibit 99.1 CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2023 and Provides Business Update · Enrollment completed for Phase 2 COVID-19 study with mono- and bivalent vaccine candidates; study on track for data read-out in early 2024 · First participant dosed in seasonal flu Phase 2 study with potentially differentiated multivalent candidate; €15 million milest |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2023 Commission File Number: 001-39446 CureVac N.V. (Exact Name of Registrant as Specified in Its Charter) Friedrich-Miescher-Strasse 15, 72076 Tübingen, Germany +49 7071 9883 0 (Address |
|
| November 14, 2023 |
Exhibit 99.1 CureVac N.V. Unaudited Interim Condensed Consolidated Financial Statements As of September 30, 2023 and December 31, 2022 and for the three and nine months ended September 30, 2023 and 2022 CureVac N.V. Interim Condensed Consolidated Statements of Operations and Other Comprehensive Income (Loss) Three months ended September 30, Nine months ended September 30, Note 2022 2023 2022 2023 |
|
| November 14, 2023 |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The following discussion and analysis of our financial condition and results of operations provides information that we believe to be relevant to an assessment and understanding of our results of operations and financial condition for the periods described. This discussion should be read in conjuncti |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2023 Commission File Number: 001-39446 CureVac N.V. (Exact Name of Registrant as Specified in Its Charter) Friedrich-Miescher-Strasse 15, 72076 Tübingen, Germany +49 7071 9883 0 (Address |
|
| November 1, 2023 |
Exhibit 99.1 CureVac Announces Solid Progress in Phase 2 COVID-19 and Seasonal Flu Clinical Development Programs in Collaboration with GSK · COVID-19 Phase 2 clinical trial fully enrolled o Study compares mono- and bivalent vaccine candidates against licensed comparator COVID-19 vaccine · First participant dosed in seasonal flu Phase 2 part of combined Phase 1/2 study o Study compares a potentiall |
|
| November 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2023 Commission File Number: 001-39446 CureVac N.V. (Exact Name of Registrant as Specified in Its Charter) Friedrich-Miescher-Strasse 15, 72076 Tübingen, Germany +49 7071 9883 0 (Address |
|
| October 12, 2023 |
Exhibit 12.1 CERTIFICATION BY THE CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Alexander Zehnder, certify that: 1. I have reviewed this annual report on Form 20-F of CureVac N.V., as amended as of the date hereof; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make |
|
| October 12, 2023 |
Consent of Independent Registered Public Accounting Firm Exhibit 15.1 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the following Registration Statements: (1) Registration Statement (Form F-3 No. 333-259613) of CureVac N.V., and (2) Registration Statement (Form S-8 No. 333-246197) as amended, pertaining to the CureVac N.V. Long-Term Incentive Plan, CureVac Virtual Share Plan, and Employment Agre |
|
| October 12, 2023 |
Exhibit 12.2 CERTIFICATION BY THE CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Pierre Kemula, certify that: 1. I have reviewed this annual report on Form 20-F of CureVac N.V., as amended as of the date hereof; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the |
|
| October 12, 2023 |
Exhibit 13.1 CERTIFICATION BY THE CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 The certification set forth below is being submitted in connection with the Annual Report on Form 20-F of CureVac N.V., as amended as of the date hereof (the “Report”) for the purpose of complying with Rule 13a-14(b) or Rule 15d-14(b) of |
|
| October 12, 2023 |
Exhibit 13.2 CERTIFICATION BY THE CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 The certification set forth below is being submitted in connection with the Annual Report on Form 20-F of CureVac N.V., as amended as of the date hereof (the “Report”) for the purpose of complying with Rule 13a-14(b) or Rule 15d-14(b) of |
|
| October 12, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F/A (Amendment No. 1) (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SEC |
|
| October 10, 2023 |
October 10, 2023 VIA EDGAR Re: CureVac N.V. Form 20-F for the Fiscal Year Ended December 31, 2022 Filed April 25, 2023 File No. 001-39446 Ms. Lynn Dicker Mr. Kevin Kuhar Division of Corporation Finance Office of Life Sciences U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Dear Ms. Dicker and Mr. Kuhar: On behalf of our client, CureVac N.V. (the “Company”), we are |
|
| September 28, 2023 |
CureVac Reports Progress in Intellectual Property Infringement Case Against BioNTech in Germany Exhibit 99.1 CureVac Reports Progress in Intellectual Property Infringement Case Against BioNTech in Germany · Regional Court Düsseldorf postpones infringement ruling on four intellectual property rights in lawsuit filed by CureVac against BioNTech · Ruling on infringement to be provided latest once the validity of the intellectual property rights in suit has been determined by the relevant patent |
|
| September 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2023 Commission File Number: 001-39446 CureVac N.V. (Exact Name of Registrant as Specified in Its Charter) Friedrich-Miescher-Strasse 15, 72076 Tübingen, Germany +49 7071 9883 0 (Address |
|
| September 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2023 Commission File Number: 001-39446 CureVac N.V. (Exact Name of Registrant as Specified in Its Charter) Friedrich-Miescher-Strasse 15, 72076 Tübingen, Germany +49 7071 9883 0 (Address |
|
| September 12, 2023 |
Exhibit 99.1 CureVac Advances Seasonal Flu Study to Phase 2 in Collaboration with GSK Following Selection of Promising mRNA Vaccine Candidate with Broad Coverage · Phase 1 part of combined Phase 1/2 study assessed comprehensive series of flu vaccine candidates, featuring up to eight separate mRNA constructs per candidate · Best-performing candidate providing broad antigen coverage against WHO-reco |
|
| August 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2023 Commission File Number: 001-39446 CureVac N.V. (Exact Name of Registrant as Specified in Its Charter) Friedrich-Miescher-Strasse 15, 72076 Tübingen, Germany +49 7071 9883 0 (Address o |
|
| August 17, 2023 |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The following discussion and analysis of our financial condition and results of operations provides information that we believe to be relevant to an assessment and understanding of our results of operations and financial condition for the periods described. This discussion should be read in conjuncti |
|
| August 17, 2023 |
Exhibit 99.1 CureVac Announces Financial Results for the Second Quarter and First Half of 2023 and Provides Business Update · Initiated Phase 2 study in COVID-19 with monovalent and bivalent, modified mRNA vaccine candidates; continued execution on infectious disease development program in collaboration with GSK · Initiated Phase 1 study of cancer vaccine candidate, CVGBM, for surgically resected |
|
| August 17, 2023 |
Exhibit 99.1 CureVac N.V. Unaudited Interim Condensed Consolidated Financial Statements As of June 30, 2023 and December 31, 2022 and for the three and six months ended June 30, 2023 and 2022 CureVac N.V. Interim Condensed Consolidated Statements of Operations and Other Comprehensive Income (Loss) Three months ended June 30, Six months ended June 30, Note 2022 2023 2022 2023 (in thousands of EUR, |
|
| August 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2023 Commission File Number: 001-39446 CureVac N.V. (Exact Name of Registrant as Specified in Its Charter) Friedrich-Miescher-Strasse 15, 72076 Tübingen, Germany +49 7071 9883 0 (Address of |
|
| August 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2023 Commission File Number: 001-39446 CureVac N.V. (Exact Name of Registrant as Specified in Its Charter) Friedrich-Miescher-Strasse 15, 72076 Tübingen, Germany +49 7071 9883 0 (Address of |
|
| August 1, 2023 |
Exhibit 99.1 CureVac Announces Dosing of First Participant in Phase 2 Study of Modified COVID-19 mRNA Vaccine Candidates Developed in Collaboration with GSK · Phase 2 study initiated at clinical sites in Australia with monovalent and bivalent mRNA COVID-19 vaccine candidates · Vaccine candidates developed in collaboration with GSK within COVID-19 vaccine development program TÜBINGEN, Germany / BOS |
|
| July 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2023 Commission File Number: 001-39446 CureVac N.V. (Exact Name of Registrant as Specified in Its Charter) Friedrich-Miescher-Strasse 15, 72076 Tübingen, Germany +49 7071 9883 0 (Address of p |
|
| July 14, 2023 |
CureVac Announces Update to the Management Team Exhibit 99.1 CureVac Announces Update to the Management Team TÜBINGEN, Germany / BOSTON, USA – July 14, 2023 – CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced that Dr. Igor Splawski, CureVac’s Chief Scientific Officer, will step down effective July 14, 2023 t |
|
| July 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2023 Commission File Number: 001-39446 CureVac N.V. (Exact Name of Registrant as Specified in Its Charter) Friedrich-Miescher-Strasse 15, 72076 Tübingen, Germany +49 7071 9883 0 (Address of p |
|
| July 13, 2023 |
Exhibit 99.1 CureVac Strengthens Ongoing Patent Litigations Bringing Additional Cases Under New Intellectual Property Rights · Cases in Germany and the U.S. broadened by asserting additional, new intellectual property rights · Three new intellectual property rights added to infringement lawsuit against Pfizer/BioNTech in Germany, increasing number of asserted intellectual property rights to eight |
|
| June 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2023 Commission File Number: 001-39446 CureVac N.V. (Exact Name of Registrant as Specified in Its Charter) Friedrich-Miescher-Strasse 15, 72076 Tübingen, Germany +49 7071 9883 0 (Address of p |
|
| June 22, 2023 |
Exhibit 99.1 CureVac N.V., Tübingen, Germany General Meeting of Shareholders, June 19, 2023 Voting results – Overview Agenda Item 3 Adoption of the annual accounts over the financial year 2022 - accepted 162.009.808 Number of shares for which valid votes were cast (= 72.37 % of the registered share capital) 161.947.876 Yes votes 99.99 % of the valid votes cast 14.771 No votes 0.0 % of the valid vo |
|
| June 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2023 Commission File Number: 001-39446 CureVac N.V. (Exact Name of Registrant as Specified in Its Charter) Friedrich-Miescher-Strasse 15, 72076 Tübingen, Germany +49 7071 9883 0 (Address of p |
|
| June 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2023 Commission File Number: 001-39446 CureVac N.V. (Exact Name of Registrant as Specified in Its Charter) Friedrich-Miescher-Strasse 15, 72076 Tübingen, Germany +49 7071 9883 0 (Address of |
|
| June 20, 2023 |
Exhibit 99.1 CureVac Doses First Patient in Phase 1 Study of Cancer Vaccine Candidate for Surgically Resected Glioblastoma · Cancer vaccine candidate CVGBM utilizes single mRNA, encoding eight epitopes of tumor-associated antigens with demonstrated relevance in glioblastoma · Study designed to evaluate safety and immunogenicity in patients with glioblastoma after surgical resection and radiotherap |
|
| June 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2023 Commission File Number: 001-39446 CureVac N.V. (Exact Name of Registrant as Specified in Its Charter) Friedrich-Miescher-Strasse 15, 72076 Tübingen, Germany +49 7071 9883 0 (Address of p |
|
| June 20, 2023 |
CureVac Appoints International Financial Expert Michael Brosnan to Supervisory Board Exhibit 99.1 CureVac Appoints International Financial Expert Michael Brosnan to Supervisory Board TÜBINGEN, Germany / BOSTON, USA – June 20, 2023 – CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced the appointment of Michael Brosnan as an independent director t |
|
| June 20, 2023 |
CureVac Announces Voting Results of General Meeting Exhibit 99.1 CureVac Announces Voting Results of General Meeting TÜBINGEN, Germany / BOSTON, USA – June 19, 2023 – CureVac N.V. (Nasdaq: CVAC), a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced the voting results of the Company's annual general meeting. The shareholders of the Company v |
|
| May 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2023 Commission File Number: 001-39446 CureVac N.V. (Exact Name of Registrant as Specified in Its Charter) Friedrich-Miescher-Strasse 15, 72076 Tübingen, Germany +49 7071 9883 0 (Address of p |
|
| May 30, 2023 |
Exhibit 99.2 Signature [PLEASE SIGN WITHIN BOX] Date Signature (Joint Owners) Date TO VOTE, MARK BLOCKS BELOW IN BLUE OR BLACK INK AS FOLLOWS: KEEP THIS PORTION FOR YOUR RECORDS DETACH AND RETURN THIS PORTION ONLY THIS PROXY CARD IS VALID ONLY WHEN SIGNED AND DATED. V18674-P96104 3. Release of supervisory directors from liability for the exercise of their duties during the financial year 2022 2. R |
|
| May 30, 2023 |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The following discussion and analysis of our financial condition and results of operations provides information that we believe to be relevant to an assessment and understanding of our results of operations and financial condition for the periods described. This discussion should be read in conjuncti |
|
| May 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2023 Commission File Number: 001-39446 CureVac N.V. (Exact Name of Registrant as Specified in Its Charter) Friedrich-Miescher-Strasse 15, 72076 Tübingen, Germany +49 7071 9883 0 (Address of p |
|
| May 30, 2023 |
Exhibit 99.1 CureVac N.V. Unaudited Interim Condensed Consolidated Financial Statements As of March 31, 2023 and December 31, 2022 and for the three months ended March 31, 2023 and 2022 CureVac N.V. Interim Condensed Consolidated Statements of Operations and Other Comprehensive Income (Loss) Three months ended March 31, Note 2022 2023 (in thousands of EUR, except per share amounts) (unaudited) Rev |
|
| May 30, 2023 |
Exhibit 99.1 CONVENING NOTICE This is the convening notice for the annual general meeting of shareholders of CureVac N.V. (the "Company") to be held at the offices of NautaDutilh N.V. (address: Beethovenstraat 400, 1082 PR Amsterdam, the Netherlands) on June 19, 2023 at 14:00 p.m. Central European Summer Time (the "AGM"). The agenda for the AGM is as follows: 1. Opening 2. Discussion of the annual |
|
| May 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2023 Commission File Number: 001-39446 CureVac N.V. (Exact Name of Registrant as Specified in Its Charter) Friedrich-Miescher-Strasse 15, 72076 Tübingen, Germany +49 7071 9883 0 (Address of pr |
|
| May 30, 2023 |
Cash and Condensed Consolidated Profit and Loss Data Exhibit 99.1 CureVac Announces Financial Results for the First Quarter of 2023 and Provides Business Update • Initiated Phase 1/2 study in seasonal flu with multivalent, modified mRNA vaccine candidates; continued execution on infectious disease development program in collaboration with GSK • Filed infringement counterclaim in U.S. patent litigation with Pfizer/BioNTech; case filed under nine Cure |
|
| May 19, 2023 |
CureVac Announces Developments in Patent Litigation with Pfizer/BioNTech Exhibit 99.1 CureVac Announces Developments in Patent Litigation with Pfizer/BioNTech · Motion to transfer U.S. litigation to Eastern District of Virginia granted at CureVac's request and expected to significantly accelerate U.S. litigation timeline · CureVac is filing counterclaim in U.S. court under nine patents covering foundational mRNA innovations highly relevant to the design, formulation an |
|
| May 19, 2023 |
6-K 1 tm2316318d16k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2023 Commission File Number: 001-39446 CureVac N.V. (Exact Name of Registrant as Specified in Its Charter) Friedrich-Miescher-Strasse 15, 72076 Tübingen, Germa |
|
| April 25, 2023 |
Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. Exhibit 12.1 CERTIFICATION BY THE CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Alexander Zehnder, certify that: 1.I have reviewed this annual report on Form 20-F of CureVac N.V.; 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the |
|
| April 25, 2023 |
Consent of Ernst & Young GmbH Wirtschaftsprüfungsgesellschaft. Exhibit 15.1 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the following Registration Statements: (1) Registration Statement (Form F-3 No. 333-259613) of CureVac N.V., and (2) Registration Statement (Form S-8 No. 333-246197) as amended, pertaining to the CureVac N.V. Long-Term Incentive Plan, CureVac Virtual Share Plan, and Employment Agre |
|
| April 25, 2023 |
EX-4.63 5 cvac-20221231xex4d63.htm EX-4.63 Exhibit 4.63 REDACTED Certain identified information, indicated by [*****], has been excluded from the exhibit because it is both (i) not material and (ii) the type that the registrant treats as private or confidential. FOURTH AMENDMENT TO SPONSORED RESEARCH AGREEMENT MEE Agreement No. 2019A009504 This fourth amendment to Agreement (the “Fourth Amendment” |
|
| April 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2023 Commission File Number: 001-39446 CureVac N.V. (Exact Name of Registrant as Specified in Its Charter) Friedrich-Miescher-Strasse 15, 72076 Tübingen, Germany +49 7071 9883 0 (Address of |
|
| April 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF |
|
| April 25, 2023 |
Research and Option Agreement, by and between CureVac AG and myNEO NV, dated May 12, 2022. Exhibit 4.61 REDACTED Certain identified information, indicated by [*****], has been excluded from the exhibit because it is both (i) not material and (ii) the type that the registrant treats as private or confidential. EXECUTION VERSION CONFIDENTIAL Research and Option Agreement by and between CureVac AG and myNEO NV EXECUTION VERSION CONFIDENTIAL RESEARCH AND OPTION AGREEMENT This Research and O |
|
| April 25, 2023 |
Exhibit 99.1 CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2022 and Provides Business Update · In 2022, ongoing business transformation driven by COVID-19 and flu clinical developments in collaboration with GSK and successful broadening of oncology footprint · Early 2023, strong validation of CureVac’s proprietary mRNA technology platform from positive preliminary Phase |
|
| April 25, 2023 |
Exhibit 13.1 CERTIFICATION BY THE CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 The certification set forth below is being submitted in connection with the Annual Report on Form 20-F of CureVac N.V. (the “Report”) for the purpose of complying with Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 19 |
|
| April 25, 2023 |
Exhibit 2.5 DESCRIPTION OF THE RIGHTS OF EACH CLASS OF SECURITIES REGISTERED UNDER SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 AS OF DECEMBER 31, 2022. As of the end of the period covered by the Annual Report on Form 20-F of which this Exhibit 2.5 is a part, CureVac N.V. (the “Company”, “we”, “us” or “our”) has only one class of securities registered under Section 12 of the Securities Exchan |
|
| April 25, 2023 |
Exhibit 4.62 EXECUTION VERSION SUBJECT TO CONTRACT REDACTED Certain identified information, indicated by [*****], has been excluded from the exhibit because it is both (i) not material and (ii) the type that the registrant treats as private or confidential. COVID CLA FOURTH AMENDMENT dated AUGUST 2022 by and between CUREVAC AG and GLAXOSMITHKLINE BIOLOGICALS SA CONTENTS Section Page 1. Interpretat |
|
| April 25, 2023 |
Exhibit 13.2 CERTIFICATION BY THE CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 The certification set forth below is being submitted in connection with the Annual Report on Form 20-F of CureVac N.V. (the “Report”) for the purpose of complying with Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 19 |
|
| April 25, 2023 |
Exhibit 15.2 April 25, 2023 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 United States Ladies and Gentlemen: We have read Item 16F of CureVac N.V.’s Form 20-F to be filed on April 25, 2023 and are in agreement with the statements contained in the first, third and fourth paragraphs therein. We have no basis to agree or disagree with other statements of the Company cont |
|
| April 25, 2023 |
Exhibit 4.64 REDACTED Certain identified information, indicated by [*****], has been excluded from the exhibit because it is both (i) not material and (ii) the type that the registrant treats as private or confidential. FIFTH AMENDMENT TO SPONSORED RESEARCH AGREEMENT MEE Agreement No. 2019A009504 This fifth amendment to Agreement (the “Fifth Amendment”), is effective as of January 1, 2023 (“Fifth |
|
| April 25, 2023 |
Certification Pursuant to Section 302 of the Sarbane-Oxley Act of 2002. Exhibit 12.2 CERTIFICATION BY THE CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Pierre Kemula, certify that: 1.I have reviewed this annual report on Form 20-F of CureVac N.V.; 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the cir |
|
| March 31, 2023 |
6-K 1 tm2311188d16k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2023 Commission File Number: 001-39446 CureVac N.V. (Exact Name of Registrant as Specified in Its Charter) Friedrich-Miescher-Strasse 15, 72076 Tübingen, Ge |
|
| March 31, 2023 |
Exhibit 99.1 CureVac N.V., Tübingen, Germany Extraordinary General Meeting of Shareholders, March 28, 2023 Voting results – Overview Agenda Item 2 Appointment of Dr. Alexander Zehnder as managing director of the Company - accepted 159.164.046 Number of shares for which valid votes were cast (= 71.10 % of the registered share capital) 159.060.946 Yes votes 99.94 % of the valid votes cast 89.959 No |
|
| March 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2023 Commission File Number: 001-39446 CureVac N.V. (Exact Name of Registrant as Specified in Its Charter) Friedrich-Miescher-Strasse 15, 72076 Tübingen, Germany +49 7071 9883 0 (Address of |
|
| March 29, 2023 |
CureVac Announces Voting Results of Extraordinary General Meeting Exhibit 99.1 CureVac Announces Voting Results of Extraordinary General Meeting TÜBINGEN, Germany / BOSTON, USA – March 28, 2023 – CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced the voting results of the Company's extraordinary general meeting. The shareholders of the Co |
|
| March 27, 2023 |
NL:CVAC / CureVac NV / RA CAPITAL MANAGEMENT, L.P. - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* CUREVAC N.V. (Name of Issuer) Common Shares, nominal value £0.12 per share (Title of Class of Securities) N2451R105 (CUSIP Number) March 15, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursu |
|
| February 27, 2023 |
EX-99.2 3 tm237725d1ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 Signature [PLEASE SIGN WITHIN BOX] Date Signature (Joint Owners) Date TO VOTE, MARK BLOCKS BELOW IN BLUE OR BLACK INK AS FOLLOWS: KEEP THIS PORTION FOR YOUR RECORDS DETACH AND RETURN THIS PORTION ONLY THIS PROXY CARD IS VALID ONLY WHEN SIGNED AND DATED. D99293-S62964 1. Appointment of Dr. Alexander Zehnder as managing director of the Company |
|
| February 27, 2023 |
EX-99.1 2 tm237725d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 CONVENING NOTICE This is the convening notice for the extraordinary general meeting of shareholders of CureVac N.V. (the "Company") to be held at the offices of NautaDutilh N.V. (address: Beethovenstraat 400, 1082 PR Amsterdam, the Netherlands) on March 28, 2023 at 14:00 Central European Time (the "EGM"). The agenda for the EGM is as follows |
|
| February 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of February, 2023 Commission File Number: 001-39446 CureVac N.V. (Exact Name of Registrant as Specified in Its Charter) Friedrich-Miescher-Strasse 15, 72076 Tübingen, Germany +49 7071 9883 0 (Address |
|
| February 24, 2023 |
NL:CVAC / CureVac NV / Hettich Christof - AMENDMENT NO. 3 TO SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. 3) CUREVAC N.V. (Name of Issuer) Common Shares, par value €0.12 per share (Title of Class of Securities) N2451R105 (CUSIP Number) Brian S. North, Esquire Buch |
|
| February 24, 2023 |
NL:CVAC / CureVac NV / KfW - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 5)* CUREVAC N.V. (Name of Issuer) Common Shares € 0.12 par value (Title of Class of Securities) N2451R105 (CUSIP Number) Pierre-Emmanuel Perais Linklaters LLP 1290 Avenue of the Americas New York, NY 10104 +1 212 903 9046 (Name, Address and Telephone Number |
|
| February 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. 7) CUREVAC N.V. (Name of Issuer) Common Shares, par value €0.12 per share (Title of Class of Securities) N2451R105 (CUSIP Number) Brian S. North, Esquire Buch |
|
| February 24, 2023 |
NL:CVAC / CureVac NV / Hothum Mathias - AMENDMENT NO. 2 TO SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. 2) CUREVAC N.V. (Name of Issuer) Common Shares, par value €0.12 per share (Title of Class of Securities) N2451R105 (CUSIP Number) Brian S. North, Esquire Buch |
|
| February 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. 3) CUREVAC N.V. (Name of Issuer) Common Shares, par value €0.12 per share (Title of Class of Securities) N2451R105 (CUSIP Number) Brian S. North, Esquire Buch |
|
| February 13, 2023 |
NL:CVAC / CureVac NV / KfW - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* CUREVAC N.V. (Name of Issuer) Common Shares € 0.12 par value (Title of Class of Securities) N2451R105 (CUSIP Number) Pierre-Emmanuel Perais Linklaters LLP 1290 Avenue of the Americas New York, NY 10104 +1 212 903 9046 (Name, Address and Telephone Number |
|
| February 10, 2023 |
Consent of Davis Polk & Wardwell LLP (included in Exhibit 8.3) Exhibit 8.3 Davis Polk & Wardwell llp 450 Lexington Avenue New York, NY 10017 davispolk.com February 10, 2023 CureVac N.V. Friedrich-Miescher-Strasse 15 72076 Tübingen Germany Ladies and Gentlemen: We are acting as United States counsel to CureVac N.V., a Dutch public company with limited liability (naamloze vennootschap) (the “Company”), in connection with the preparation of the prospectus supple |
|
| February 10, 2023 |
Exhibit 1.1 Execution Version CureVac N.V. (a Dutch company) 27,027,028 Common Shares UNDERWRITING AGREEMENT Dated: February 7, 2023 CureVac N.V. (a Dutch company) 27,027,028 Common Shares UNDERWRITING AGREEMENT February 7, 2023 Goldman Sachs & Co. LLC Jefferies LLC SVB Securities LLC as Representatives of the several Underwriters c/o Goldman Sachs & Co. LLC 200 West Street New York, New York 1028 |
|
| February 10, 2023 |
CureVac Announces Closing of $250 million Follow-on Public Offering of Common Shares EX-99.1 7 tm236242d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 CureVac Announces Closing of $250 million Follow-on Public Offering of Common Shares TÜBINGEN, Germany/ BOSTON, USA – February 10, 2023 – CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), announced today the closing of i |
|
| February 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2023 Commission File Number: 001-39446 CureVac N.V. (Exact Name of Registrant as Specified in Its Charter) Friedrich-Miescher-Strasse 15, 72076 Tübingen, Germany +49 7071 9883 0 (Address |
|
| February 9, 2023 |
Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) CUREVAC N.V. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Reg |
|
| February 9, 2023 |
CureVac N.V. 27,027,028 Common Shares TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-259613 PROSPECTUS SUPPLEMENT (To Prospectus Dated September 17, 2021) CureVac N.V. 27,027,028 Common Shares We are offering 27,027,028 common shares, nominal value €0.12 per share. Our common shares are listed on The Nasdaq Global Market (“Nasdaq”) under the symbol “CVAC.” On February 7, 2023, the last reported sale price of |
|
| February 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of February, 2023 Commission File Number: 001-39446 CureVac N.V. (Exact Name of Registrant as Specified in Its Charter) Friedrich-Miescher-Strasse 15, 72076 Tübingen, Germany +49 7071 9883 0 (Address |
|
| February 8, 2023 |
CureVac Announces Pricing of Upsized Public Offering of Common Shares Exhibit 99.1 CureVac Announces Pricing of Upsized Public Offering of Common Shares TÜBINGEN, Germany/ BOSTON, USA – February 7, 2023 – CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), announced today the pricing of 27,027,028 common shares in an underwritten public offering a |
|
| February 6, 2023 |
CureVac Announces Proposed Public Offering of Common Shares Exhibit 99.1 CureVac Announces Proposed Public Offering of Common Shares TÜBINGEN, Germany/BOSTON, USA – February 6, 2023 – CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), announced today that it intends to offer $200 million of its common shares in an underwritten public of |
|
| February 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of February, 2023 Commission File Number: 001-39446 CureVac N.V. (Exact Name of Registrant as Specified in Its Charter) Friedrich-Miescher-Strasse 15, 72076 Tübingen, Germany +49 7071 9883 0 (Address |
|
| February 6, 2023 |
SUBJECT TO COMPLETION, DATED FEBRUARY 6, 2023. TABLE OF CONTENTS The information in this preliminary prospectus supplement and accompanying prospectus is not complete and may be changed. |
|
| February 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2023 Commission File Number: 001-39446 CureVac N.V. (Exact Name of Registrant as Specified in Its Charter) Friedrich-Miescher-Strasse 15, 72076 Tübingen, Germany +49 7071 9883 0 (Address |
|
| February 1, 2023 |
CureVac Welcomes Myriam Mendila as New Chief Development Officer Exhibit 99.1 CureVac Welcomes Myriam Mendila as New Chief Development Officer · Dr. Mendila joins CureVac as Chief Development Officer with more than 20 years of global industry experience TÜBINGEN, Germany/ BOSTON, USA – February 1, 2023 – CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”) |
|
| January 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2023 Commission File Number: 001-39446 CureVac N.V. (Exact Name of Registrant as Specified in Its Charter) Friedrich-Miescher-Strasse 15, 72076 Tübingen, Germany +49 7071 9883 0 (Address o |
|
| January 31, 2023 |
CureVac Named as One of the World’s Most Dynamic Innovators by LexisNexis Exhibit 99.1 CureVac Named as One of the World’s Most Dynamic Innovators by LexisNexis · CureVac recognized as a Top 100 innovator in acknowledgment of the company’s innovative strength and extensive intellectual property portfolio · The company holds one of broadest intellectual property portfolios in mRNA technology TÜBINGEN, Germany/ BOSTON, USA – January 31, 2023 – CureVac N.V. (Nasdaq: CVAC), |
|
| January 30, 2023 |
Exhibit 99.2 January 30, 2023 Extended Preliminary Phase 1 Data from Joint COVID - 19 and Flu mRNA Vaccine Development Programs The information set forth herein does not purport to be complete or to contain all of the information you may desire. Statements contained herein are made as of the date of this document unless stated otherwise, and neither the delivery of this document at any time, nor a |
|
| January 30, 2023 |
Exhibit 99.1 CureVac Announces Positive Data in Older Adults from COVID-19 and Flu mRNA Vaccine Development Programs • Continued technology platform validation with extended preliminary data from older adults in ongoing Phase 1 studies in COVID-19 and flu • COVID-19: monovalent modified mRNA construct CV0501 successfully boosted antibody titers against BA.1 and ancestral variants in adults age ≥65 |
|
| January 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2023 Commission File Number: 001-39446 CureVac N.V. (Exact Name of Registrant as Specified in Its Charter) Friedrich-Miescher-Strasse 15, 72076 Tübingen, Germany +49 7071 9883 0 (Address o |
|
| January 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2023 Commission File Number: 001-39446 CureVac N.V. (Exact Name of Registrant as Specified in Its Charter) Friedrich-Miescher-Strasse 15, 72076 Tübingen, Germany +49 7071 9883 0 (Address o |
|
| January 9, 2023 |
CureVac Appoints Alexander Zehnder as CEO From April 1, 2023 Exhibit 99.1 CureVac Appoints Alexander Zehnder as CEO From April 1, 2023 · Dr. Franz-Werner Haas to complete successful tenure as CEO by March 31, 2023 · Dr. Alexander Zehnder to succeed Dr. Haas as new CEO, joining from Sanofi on April 1, 2023 TÜBINGEN, Germany/ BOSTON, USA – January 9, 2023 – CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformativ |
|
| January 6, 2023 |
CureVac Announces Positive Data on Joint COVID-19 and Flu mRNA Vaccine Development Programs Exhibit 99.1 CureVac Announces Positive Data on Joint COVID-19 and Flu mRNA Vaccine Development Programs ? Promising COVID-19 and flu modified mRNA vaccine candidates identified based on positive preliminary data from ongoing Phase 1 studies ? All candidates use CureVac?s advanced second-generation mRNA backbone optimized to achieve improved mRNA translation and strong immune responses at low dose |
|
| January 6, 2023 |
6-K 1 tm232385d16k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2023 Commission File Number: 001-39446 CureVac N.V. (Exact Name of Registrant as Specified in Its Charter) Friedrich-Miescher-Strasse 15, 72076 Tübingen, Ge |
|
| December 14, 2022 |
6-K 1 tm2232556d16k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2022 Commission File Number: 001-39446 CureVac N.V. (Exact Name of Registrant as Specified in Its Charter) Friedrich-Miescher-Strasse 15, 72076 Tübingen, |
|
| December 14, 2022 |
CureVac Members of Management Sell Shares to Cover Tax Obligations from Long Term Incentive Program Exhibit 99.1 CureVac Members of Management Sell Shares to Cover Tax Obligations from Long Term Incentive Program T?BINGEN, Germany/ Boston, USA ? December 14, 2022 - CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (?mRNA?), today announced that Chief Executive Officer Franz-Werner Haas, Chief Fin |
|
| November 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2022 Commission File Number: 001-39446 CureVac N.V. (Exact Name of Registrant as Specified in Its Charter) Friedrich-Miescher-Strasse 15, 72076 T?bingen, Germany +49 7071 9883 0 (Address |
|
| November 17, 2022 |
Exhibit 99.3 EXPLANATORY NOTE This ?Material Dutch Tax Considerations? section is being provided to update the disclosure in CureVac?s Annual Report on Form 20-F for the year ended December 31, 2021 as filed with the U.S. Securities and Exchange Commission on April 28, 2022 as a result of subsequent changes in Dutch tax law. This section shall be deemed to be incorporated by reference into CureVac |
|
| November 17, 2022 |
? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? FORM 6-K ? REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 ? For the month of November, 2022 Commission File Number: 001-39446 ? CureVac N.V. (Exact Name of Registrant as Specified in Its Charter) ? Friedrich-Miescher-Strasse 15, 72076 T?bingen, Germany +49 7071 9 |
|
| November 17, 2022 |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS ? Exhibit 99.2 MANAGEMENT?S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The following discussion and analysis of our financial condition and results of operations provides information that we believe to be relevant to an assessment and understanding of our results of operations and financial condition for the periods described. This discussion should be read in conjunc |
|
| November 17, 2022 |
Exhibit 99.1 CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2022 and Provides Business Update ? Delivering on broad second-generation vaccine development program with expansion into modified mRNA technology in collaboration with GSK o Phase 1 studies in influenza and COVID-19 on track to deliver clinical data in Q1 2023 ? Strengthening oncology position based on |
|
| November 17, 2022 |
? Exhibit 99.1 ? ? CureVac N.V. Unaudited Interim Condensed Consolidated Financial Statements As of September 30, 2022 and December 31, 2021 and for the nine months ended September 30, 2022 and 2021 ? ? ? CureVac N.V. Interim Condensed Consolidated Statements of Operations and Other Comprehensive Income (Loss) ? ? ? ? ? ? ? ? ? ? Nine months ended September 30, ? Note 2021 2022 (in thousands of EU |
|
| November 14, 2022 |
CureVac Presents Preliminary Data from Phase 1 Study Expansion of Oncology Candidate CV8102 Exhibit 99.1 CureVac Presents Preliminary Data from Phase 1 Study Expansion of Oncology Candidate CV8102 ? Data confirm CV8102?s safety and ability to strongly mobilize the immune system against tumors ? Final data of complete Phase 1 dose-escalation and expansion study expected in H1 2023 T?BINGEN, Germany/ Boston, USA ? November 11, 2022 - CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2022 Commission File Number: 001-39446 CureVac N.V. (Exact Name of Registrant as Specified in Its Charter) Friedrich-Miescher-Strasse 15, 72076 T?bingen, Germany +49 7071 9883 0 (Address |
|
| November 14, 2022 |
NL:CVAC / CureVac NV / Hothum Mathias - AMENDMENT NO. 1 TO SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. 1) CUREVAC N.V. (Name of Issuer) Common Shares, par value €0.12 per share (Title of Class of Securities) N2451R105 (CUSIP Number) Brian S. North, Esquire Buch |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. 2) CUREVAC N.V. (Name of Issuer) Common Shares, par value €0.12 per share (Title of Class of Securities) N2451R105 (CUSIP Number) Brian S. North, Esquire Buch |
|
| November 14, 2022 |
NL:CVAC / CureVac NV / Hettich Christof - AMENDMENT NO. 2 TO SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. 2) CUREVAC N.V. (Name of Issuer) Common Shares, par value €0.12 per share (Title of Class of Securities) N2451R105 (CUSIP Number) Brian S. North, Esquire Buch |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. 6) CUREVAC N.V. (Name of Issuer) Common Shares, par value €0.12 per share (Title of Class of Securities) N2451R105 (CUSIP Number) Brian S. North, Esquire Buch |
|
| August 18, 2022 |
? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K ? REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 ? For the month of August 2022 Commission File Number: 001-39446 ? CureVac N.V. (Exact Name of Registrant as Specified in Its Charter) ? Friedrich-Miescher-Strasse 15, 72076 T?bingen, Germany +49 7071 9883 0 |
|
| August 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2022 Commission File Number: 001-39446 CureVac N.V. (Exact Name of Registrant as Specified in Its Charter) Friedrich-Miescher-Strasse 15, 72076 T?bingen, Germany +49 7071 9883 0 (Address of |
|
| August 18, 2022 |
6-K 1 tm2224098d16k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2022 Commission File Number: 001-39446 CureVac N.V. (Exact Name of Registrant as Specified in Its Charter) Friedrich-Miescher-Strasse 15, 72076 Tübingen, Ge |
|
| August 18, 2022 |
CureVac Starts Phase 1 Clinical Study of Modified, Omicron-Targeting COVID-19 Vaccine Candidate Exhibit 99.1 CureVac Starts Phase 1 Clinical Study of Modified, Omicron-Targeting COVID-19 Vaccine Candidate ? Phase 1 dose-escalation study to be conducted at clinical sites in the U.S., the UK, Australia, and the Philippines ? Milestone demonstrates CureVac?s continued execution on comprehensive clinical program of second-generation vaccine candidates for infectious diseases T?BINGEN, Germany/ B |
|
| August 18, 2022 |
Exhibit 99.1 CureVac Announces Financial Results for the Second Quarter and First Half of 2022 and Provides Business Update ? Delivering on broad 2022 second-generation vaccine development program with expansion into modified mRNA technology in collaboration with GSK; new candidates in COVID-19 and influenza enter clinical studies o Phase 1 initiated for modified COVID-19 vaccine candidate CV0501, |
|
| August 18, 2022 |
? CureVac N.V. Unaudited Interim Condensed Consolidated Financial Statements As of June 30, 2022 and for the six months ended June 30, 2022 and 2021 ? ? ? CureVac N.V. Interim Condensed Consolidated Statements of Operations and Other Comprehensive Income (Loss) ? ? ? ? ? ? ? ? ? ? Six months ended June 30, ? Note 2021 2022 (in thousands of EUR, except per share amounts) ? ? ? (unaudited) Revenue ? |
